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were identified. Patients were required to have ≥ 365 day of continuous enrollment 
prior to and ≥ 730 days after the index date (date of the first claim), a claim with a 
T2DM diagnosis (ICD-9-CM 250.x0, 250.x2) and no claims for a DPP-4i medication 
prior to the index date. All-cause and diabetes-related total costs were captured over 
one-year and two-year follow-up periods. Generalized linear models with log link 
and gamma distribution were fit to compare costs between the two cohorts, control-
ling for patient baseline characteristics. Results: The final sample comprised 3,354 
saxagliptin initiators and 26,895 sitagliptin initiators. The average age of saxagliptin 
and sitagliptin initiators was 57 years old and just over 50% were males. After adjust-
ing for baseline characteristics, saxagliptin patients had significantly lower average 
all-cause medical costs over the one-year ($8,406 vs. $9,368, p< 0.0001) and two-year 
follow-up ($17,367 vs. $19,410, p< 0.0001) compared with sitagliptin patients. Total 
costs were lower for saxagliptin initiators over the one-year ($13,644 vs. $14,388, 
p= 0.0015) and two-year follow-up ($27,491 vs. $29,198, p= 0.0002). Findings were 
consistent for diabetes-related medical costs (one-year: $2,097 vs. $2,370, p< 0.0001; 
two-year: $4,312 vs. $4,753, p= 0.0003) and total diabetes-related costs (one-year: 
$4,210 vs. $4,417, p= 0.0048; two-year: $8,391 vs. $8,701, p= 0.0326). ConClusions: 
Initiation of treatment with saxagliptin was associated with lower medical costs 
over one and two years compared with sitagliptin.
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objeCtives: Portfolio management is commonly used to prioritize investments 
within the private sector, but is not used widely to manage public research invest-
ments due to the difficulty of defining and quantifying appropriate measures 
of risk and return. We recently developed a novel tools to estimate the risk and 
return of publicly funded cancer clinical trials. Our objective was to use these 
metrics and apply a proof of concept portfolio management approach within 
SWOG, a large cancer clinical trials cooperative group. Methods: The sample 
portfolio included 9 randomized Phase II/III clinical trial concepts reviewed by 
SWOG between 2008-2013, of which 5 were approved and 4 were not. Risk was 
defined as the probability of insufficient accrual (< 50% of target) and measured 
using a previously validated prediction model. Value of Information methods were 
used to estimate societal return, defined both as the population-level expected 
health benefits (clinical return) or clinical and economic benefits (net return) of 
acquiring additional information to inform a decision and measured. We com-
pared the risk-adjusted expected returns of the observed portfolio of approved 
trials to hypothetical alternative portfolios in which different trials might have 
been funded. Results: The clinical return of SWOG’s sample portfolio was valued 
at $11.3 billion. A hypothetical alternative portfolio of trials requiring 200 fewer 
patients than the observed portfolio was expected to have a clinical return of $26.3 
billion. The net return of SWOG’s observed sample portfolio was $2.7 billion. An 
alternative hypothetical portfolio that includes four trials and requires 400 fewer 
patients than the observed portfolio was expected to have a net return of approxi-
mately $9.6 billion. ConClusions: A portfolio management approach appears 
to be a feasible and potentially useful response to the Institute of Medicine’s call 
for more systematic approaches to prioritize trials concepts within the cancer 
clinical trials cooperative groups.
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objeCtives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. Methods: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 per 
QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the maxi-
mum accepted thresholds for end of life care therapies. ConClusions: Review of 
cost effectiveness studies for ultra orphan therapies shows that none were able to 
show ICERs within typical thresholds. These results suggest a need for new policy 
regarding acceptable threshold, or type of models for assessing the cost effective-
ness of ultra orphan therapies.
patient costing), more details on the various cost components and sources of 
data, and considerations for costing based on economic evaluation considera-
tions (e.g. setting, perspective). ConClusions: The 2nd edition of the Guidance 
Document aims to better assist Canadian researchers in appropriately identifying, 
measuring, and sourcing the types of costs and resources relevant for economic 
evaluations.
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objeCtives: The Centers for Disease Control and Prevention reported that the costs 
attributable to Chronic Obstructive Pulmonary Disease (COPD) are projected to be 
$49.0 billion by 2020. This retrospective claims analysis characterized and compared 
Medicare beneficiaries with high and low healthcare resource utilization (HCRU) as 
a means to inform the drivers of this large economic burden. Methods: Medicare 
beneficiaries with a COPD diagnosis in 2012 were identified in the Centers for 
Medicare and Medicaid Services (CMS) claims databases. HCRU groups were defined 
based on the total payment amount across the inpatient, outpatient and physician 
office settings; high and low utilizers represented the top and bottom quartiles, 
respectively. The utilization groups were compared across patient demographics, 
comorbidities and HCRU using t-tests. A classification tree was fitted to identify the 
patient risk factors that were the biggest drivers of differences in HCRU. Results: 
Overall, 257,752 COPD patients were identified, with 64,438 patients in each of 
the high and low utilization groups. The mean (95% confidence interval) payment 
amounts for high and low utilizers were $54,176 ($53,847, $54,506) and $1,131 ($1,126, 
$1,136), respectively. On average, high utilizers had a significantly (p< 0.001) higher 
number of claims, longer length of stay, higher Charlson Comorbidity Index (CCI) 
score and more complicated comorbid respiratory conditions and medical proce-
dures (102, 19, 6, 60%, 21%) relative to low utilizers (16, 0, 2, 23%, 4%). The classifica-
tion tree identified the most important risk factors in differentiating high and low 
utilizers as CCI score, comorbid anemia, COPD complexity, comorbid pneumonia 
and heart failure. ConClusions: HCRU among COPD Medicare patients varied 
greatly, with high utilizers tending to be sicker across all comorbidity measures. The 
classification tree analysis indicated that comorbidities such as anemia, pneumonia 
and heart failure are more highly associated with HCRU than demographic factors, 
such as age, gender and race.
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objeCtives: This study compared home healthcare use and expenditures 
among elderly Medicare beneficiaries with and without Parkinson’s disease 
(PD) and analyzed the extent to which individual-level factors contribute to 
the excess home healthcare use and expenditures among individuals with 
PD. Methods: A retrospective, observational, cohort study was conducted using 
Medicare 5% sample claims database with baseline (year 2006) and follow-up 
(year 2007) period. The study sample included elderly (age > 65 years) fee-for-
service Medicare beneficiaries continuously enrolled in Medicare Part A and B for 
2006 and 2007. Elderly Medicare beneficiaries with PD were identified based on 
the ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical 
Modification) codes of 332.xx during baseline. All the independent variables were 
measured during baseline. The dependent variables (home healthcare use and 
expenditures) were measured in 2007. Logistic regressions and Ordinary Least 
Square regressions were used to assess the association of PD with home health 
use and expenditures respectively. Post regression non-linear and linear decom-
position techniques were used to understand the extent to which differences 
in home healthcare use and expenditures among elderly Medicare beneficiar-
ies with and without PD can be explained by individual-level factors. Results: 
Elderly Medicare beneficiaries with PD had 13.3 percentage point higher home 
healthcare use, of which 27.5% were explained by differences in characteristics 
between the two groups. Among home healthcare users, those with PD had greater 
expenditures ($6,792) compared to those without PD ($4,965). Only 18% of the 
difference in home healthcare expenditures were explained by differences in 
characteristics between the two groups. Baseline resource use and comorbidi-
ties explained majority of the differences in home healthcare use and expendi-
tures. ConClusions: These findings underscore the importance of developing 
interventions such as using appropriate evidence based co-management of multi-
ple chronic conditions and need of interdisciplinary team collaboration to provide 
better care.
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objeCtives: To compare all-cause and diabetes-related utilization and costs fol-
lowing initiation of the dipeptidyl peptidase-4 inhibitors saxagliptin or sitagliptin 
in the treatment of type 2 diabetes (T2DM). Methods: Patients aged 18+ with ≥ 1 
prescription claim for saxagliptin or sitagliptin between 1/1/2009 and 1/31/2012 in 
the Truven Health MarketScan Commercial and Medicare Supplemental databases 
